Inhibition of Th17 cells by donepezil ameliorates experimental lung fibrosis and pulmonary hypertension

Rationale: Pulmonary hypertension (PH) secondary to lung fibrosis belongs to WHO Group III, one of the most common subgroups of PH; however, it lacks effective treatment options. Cholinesterase inhibitor donepezil (DON) has been shown to effectively improve Group I PH. However, its effects on Group...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Yuan, He, Ziyu, Chen, Zhu, Chen, Fengling, Wang, Chengming, Zhou, Wanlu, Liu, Jie, Liu, Hao, Shi, Ruizheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2023
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10091879/
https://www.ncbi.nlm.nih.gov/pubmed/37064881
http://dx.doi.org/10.7150/thno.82069

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10091879/
https://www.ncbi.nlm.nih.gov/pubmed/37064881
http://dx.doi.org/10.7150/thno.82069

Ejemplares similares